Work

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia

Year: 2015

Type: article

Study design: Clinical Trial

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.3109/10428194.2015.1048441

Authors: Jennifer R. Brown, Bethany Tesar, Lijian Yu, Lillian Werner, Naoko Takebe, Evgeny Mikler, Hazel M. Reynolds, Christina Thompson, David C. Fisher, Donna Neuberg, A. S. Freedman

Institutions: Harvard University, Dana-Farber Cancer Institute, National Institutes of Health, National Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: American Society of Hematology, National Institutes of Health, National Center for Chronic Disease Prevention and Health Promotion

Award: G1462722688

OpenAlex ID: W1862870226

FWCI: 1.965

Cites: 37

Cited by: 42

Related to: 10